Retatrutide (LY3437943) is a synthetic triple incretin receptor agonist that simultaneously targets the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple-agonist mechanism differentiates it from dual-agonist compounds and positions it as a subject of significant research interest in the field of metabolic disease research. Retatrutide has been under active clinical investigation for its effects on energy balance, glycemic control, and cardiovascular metabolic markers.

Research examining Retatrutide has focused on its modulation of food-intake signaling via GLP-1 and GIP receptor-mediated pathways alongside increased energy expenditure through glucagon receptor activation. Preclinical data has characterized its effects on adiposity in animal models, and clinical trial data has examined body-composition endpoints in human research subjects. Studies have also examined its effects on hepatic lipid content, insulin sensitivity, and cardiovascular risk markers.

Retatrutide represents the frontier of incretin-based metabolic research and is a commonly referenced compound in studies examining GLP-1/GIP/glucagon receptor pharmacology, metabolic biology, and cardiometabolic research. This 10mg research preparation is intended for use in preclinical and in vitro studies.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.